Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.42 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4340073 | 0.91 | TNF (0.50) | TNFHTTPOLBL3MBTL1KDM4E | |
| SCHEMBL643777 | 0.91 | TNF (0.50) | TNFHTTPOLBL3MBTL1KDM4E | |
| SCHEMBL29620246 | 0.89 | HTT (0.52) | HTTPOLBL3MBTL1KDM4ELMNA | |
| SCHEMBL2468068 | 0.89 | HTT (0.52) | HTTPOLBL3MBTL1KDM4ELMNA | |
| SCHEMBL14331200 | 0.87 | TNF (0.52) | TNFHTTPOLBL3MBTL1KDM4E | |
| SCHEMBL20631194 | 0.86 | HTT (0.51) | HTTPOLBLMNANPC1CYP3A4 | |
| SCHEMBL16067368 | 0.86 | HTT (0.51) | HTTPOLBL3MBTL1LMNACASP3 | |
| SCHEMBL12221992 | 0.85 | HTT (0.47) | HTTPOLBL3MBTL1KDM4ELMNA | |
| SCHEMBL1742989 | 0.85 | POLB (0.47) | HTTPOLBL3MBTL1KDM4ELMNA | |
| SCHEMBL32690852 | 0.85 | HTT (0.50) | TNFHTTPOLBKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583857-B2 | Anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | PHEON THERAPEUTICS LTD (GB) | 2026-03-24 | — | — | US | disclosed |
| US-20250011317-A1 | ANTI-PROLIFERATIVE AGENTS | PHEON THERAPEUTICS LTD (GB) | 2025-01-09 | — | — | US | disclosed |
| US-11912700-B2 | Anti-proliferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | PHEON THERAPEUTICS LTD (GB) | 2024-02-27 | — | — | US | disclosed |
| US-11912700-B2 | Anti-proliferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | PHEON THERAPEUTICS LTD (GB) | 2024-02-27 | — | — | US | disclosed |
| US-11912700-B2 | Anti-proliferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | PHEON THERAPEUTICS LTD (GB) | 2024-02-27 | — | — | US | disclosed |
| US-20240002379-A1 | ASYMMETRIC CONJUGATE COMPOUNDS | PHEON THERAPEUTICS LTD (GB) | 2024-01-04 | — | — | US | disclosed |
| EP-4086251-A1 | PIPERIDINOBENZODIAZEPINE COMPOUNDS WITH ANTI PROLIFERATIVE ACTIVITY | Femtogenix Limited (GB) | 2022-11-09 | — | — | EP | disclosed |
| CN-114907345-A | Piperidine-benzodiazepine compound having anti-proliferative activity | 福姆通格尼克斯有限公司 | 2022-08-16 | — | — | CN | disclosed |
| EP-3337795-B1 | PIPERIDINOBENZODIAZEPINE COMPOUNDS WITH ANTI PROLIFERATIVE ACTIVITY | FEMTOGENIX LTD (GB) | 2022-06-22 | — | — | EP | disclosed |
| US-20210206763-A1 | Anti-Proliferative Agents | PHEON THERAPEUTICS LTD (GB) | 2021-07-08 | — | — | US | disclosed |
| US-20190144443-A1 | ASYMMETRIC CONJUGATE COMPOUNDS | PHEON THERAPEUTICS LTD (GB) | 2019-05-16 | — | — | US | disclosed |
| US-20190144443-A1 | ASYMMETRIC CONJUGATE COMPOUNDS | PHEON THERAPEUTICS LTD (GB) | 2019-05-16 | — | — | US | disclosed |
| EP-3455225-A1 | ASYMMETRIC CONJUGATE COMPOUNDS | Femtogenix Limited (GB) | 2019-03-20 | — | — | EP | disclosed |
| US-20180339985-A1 | PDD COMPOUNDS | FEMTOGENIX LIMITED (GB) | 2018-11-29 | — | — | US | disclosed |
| US-20180291021-A1 | PDD COMPOUNDS | PHEON THERAPEUTICS LTD (GB) | 2018-10-11 | — | — | US | disclosed |
| EP-3337795-A1 | PIPERIDINOBENZODIAZEPINE COMPOUNDS WITH ANTI PROLIFERATIVE ACTIVITY | Femtogenix Limited (GB) | 2018-06-27 | — | — | EP | disclosed |
| WO-2017194960-A1 | ASYMMETRIC CONJUGATE COMPOUNDS | FEMTOGENIX LIMITED (GB) | 2017-11-16 | — | — | WO | disclosed |
| WO-2017194960-A1 | ASYMMETRIC CONJUGATE COMPOUNDS | FEMTOGENIX LIMITED (GB) | 2017-11-16 | — | — | WO | disclosed |
| WO-2017032983-A1 | PIPERIDINOBENZODIAZEPINE COMPOUNDS WITH ANTI PROLIFERATIVE ACTIVITY | FEMTOGENIX LIMITED (GB) | 2017-03-02 | — | — | WO | disclosed |
| WO-2017032983-A1 | PIPERIDINOBENZODIAZEPINE COMPOUNDS WITH ANTI PROLIFERATIVE ACTIVITY | FEMTOGENIX LIMITED (GB) | 2017-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206763-A1 | Anti-Proliferative Agents | CCND2, BRD2, DRD2 | TNF 2091/4885HTT 3499/4885POLB 127/4885 |
| US-12583857-B2 | Anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | CNR1, MTNR1B, MTNR1A | TNF 3062/4885HTT 3054/4885POLB 2395/4885 |
| US-20250011317-A1 | ANTI-PROLIFERATIVE AGENTS | CCND2, BRD2, CCND3 | TNF 1997/4885HTT 3670/4885POLB 104/4885 |
| US-20240002379-A1 | ASYMMETRIC CONJUGATE COMPOUNDS | TUBA1C, MTX2, CCNO | TNF 1985/4885HTT 3874/4885POLB 3290/4885 |
| US-20180291021-A1 | PDD COMPOUNDS | DRD1, DRD3, DRD2 | TNF 3150/4885HTT 2338/4885POLB 1536/4885 |
| US-20190144443-A1 | ASYMMETRIC CONJUGATE COMPOUNDS | TUBA1C, MTX2, CCNO | TNF 2002/4885HTT 3888/4885POLB 3350/4885 |
| US-11912700-B2 | Anti-proliferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | MKI67, CCND2, CCND1 | TNF 3768/4885HTT 3377/4885POLB 231/4885 |
| US-20180339985-A1 | PDD COMPOUNDS | DRD1, DRD3, DRD2 | TNF 3066/4885HTT 2611/4885POLB 1301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.